Citius Pharmaceuticals, Inc.
CTXRNasdaq
$0.50
↓ -2.9%Jul 17 close · end-of-day
Price
1Y↓ -66.7%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
$11.1M
Enterprise Value
$6.5M
P/E
—
P/S
—
P/B
0.2
EV/EBITDA
—
PEG
—
FCF Yield
—
Dividend Yield
—
Revenue (TTM)
—
Net Income (TTM)
—
Free Cash Flow (TTM)
—
Gross Margin
—
Operating Margin
—
Net Margin
—
ROE
—
ROIC
-81.1%
Debt / Equity
—
Net Cash
$4.6M
Return 1Y
-68.9%
Company profile
Citius Pharmaceuticals, Inc. engages in the development and commercialization of critical care products. The company is developing five proprietary products, including Mino-Lok, an antibiotic lock solution to treat patients with catheter-related bloodstream infections by salvaging the infected catheter. MinoWrap, a liquifying gel-based wrap for reduction of tissue expander infections following breast reconstructive surgeries, and Halo-Lido, a corticosteroid-lidocaine topical formulation.
- CEO
- Leonard L. Mazur
- Sector
- Manufacturing
- Industry
- Pharmaceutical Products
- Employees
- 20
- Headquarters
- New Jersey
- Website
- citiuspharma.com
Earnings
CTXR Q2 2026 Earnings
Period ends 2026-03-31
MetricActualYoY
Revenue$1.7M—
Diluted EPS-$0.95↓ -25.2%
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
Financial statements
| Line item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Revenue | $90,000.00 | $90,000.00 | $90,000.00 | — | — | — |
| Gross profit | — | — | — | — | — | — |
| Operating income | -$17.7M | -$23.5M | -$33.3M | -$36.7M | -$42.0M | -$38.5M |
| Net income | -$17.5M | -$23.1M | -$33.6M | -$32.5M | — | — |
| Diluted EPS | — | -$0.23 | -$0.23 | -$5.57 | -$5.97 | -$3.38 |
| Operating cash flow | -$16.9M | -$24.3M | -$28.4M | -$29.1M | -$28.2M | -$26.6M |
| Free cash flow | -$16.9M | -$24.3M | — | — | — | — |
| Gross margin | — | — | — | — | — | — |
| Operating margin | -19678.5% | -26146.5% | -37017.8% | — | — | — |
| Net margin | -19497.9% | -25616.0% | -37378.5% | — | — | — |
| Line item | Q3 '24 | Q4 '24 | Q1 '24 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '25 | Q2 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | $3.9M | $1.7M |
| Gross profit | — | — | — | — | — | — | $3.2M | $1.3M |
| Operating income | -$10.6M | -$11.1M | -$10.0M | -$11.3M | -$8.8M | -$8.4M | -$9.0M | -$32.2M |
| Net income | -$10.6M | — | -$10.3M | -$11.5M | — | — | — | — |
| Diluted EPS | -$1.57 | -$1.61 | -$1.30 | -$1.27 | -$0.80 | -$0.01 | -$0.38 | -$0.95 |
| Operating cash flow | -$8.4M | -$5.9M | -$4.7M | -$4.5M | -$5.4M | -$11.9M | -$13.0M | -$1.3M |
| Free cash flow | — | — | — | — | — | — | — | — |
| Gross margin | — | — | — | — | — | — | 80.0% | 80.3% |
| Operating margin | — | — | — | — | — | — | -228.7% | -1931.0% |
| Net margin | — | — | — | — | — | — | — | — |
Company news
May 15, 2026
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
No insider transactions in the last 12 months.
No insider transactions on file.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.